-
Mashup Score: 1
The use of tumor-informed circulating tumor DNA (ctDNA) testing in early-stage patients before surgery is limited mainly due to restricted tissue access and extended turnaround times. This study aimed to evaluate the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in a large cohort of patients with resected non-small cell lung cancer (NSCLC).
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 13How Can We Conquer Lung Cancer? - 9 day(s) ago
Lung Cancer Awareness Day, initiated in 1995 by the Alliance for Lung Cancer Advocacy Support and Education (in collaboration with the American Cancer Society) in their smoking cessation efforts and later extended into Lung Cancer Awareness Month, is now observed globally. As we celebrate Lung Cancer Awareness Month this November 2024, let us review how we can achieve the International Association for the Study of Lung Cancer’s mission of Conquering Lung Cancer Worldwide.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
To celebrate Lung Cancer Awareness Month (#LCAM24), @JTOonline Editor-in-Chief @DrAlexAdjei discusses how we can achieve the #IASLC mission of "Conquering #LungCancer Worldwide" in an editorial published in November. Read More: https://t.co/vdnKDrTflW #LCAM @OncologyAdvance #LCSM https://t.co/XPJHQ4puB3
-
-
Mashup Score: 13Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC - 21 day(s) ago
The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of consolidation CPI remains unknown. Here, we characterized the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical outcomes of patients with unresectable locally advanced non-small cell lung cancer treated on a phase 2 trial of short-course consolidation immunotherapy after CRT, with the goal of testing whether ctDNA may be able to identify patients who do not require a full year of treatment.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Analyzing pts w/unresectable locally advanced #NSCLC on a phase 2 trial of short course consolidation immunotherapy after CRT, the authors found that ctDNA MRD is highly prognostic & might enable personalizing the duration of treatment. https://t.co/KaFvs9VsEI #LCSM @max_diehn https://t.co/V4nhQtbH9Y
-
-
Mashup Score: 6Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations - 22 day(s) ago
Germline mutations driving lung cancer have been infrequently reported in the literature, with EGFR T790M being a known germline mutation identified in 1% of NSCLCs. Typically, a somatic EGFR mutation is acquired to develop lung adenocarcinoma. Osimertinib has become a standard-of-care treatment for EGFR T790M-positive lung cancer.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
In this retrospective analysis through the #LungCancer Moon Shot GEMINI database @ the @MDAndersonNews Xiuning Le et al. found that osimertinib for advanced germline EGFR-mutated #NSCLC renders similar PFS compared to somatic T790M EGFR-mutated NSCLC.https://t.co/saMQYqSivW #LCSM https://t.co/AyW6pbr2u5
-
-
Mashup Score: 13Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC - 24 day(s) ago
The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of consolidation CPI remains unknown. Here, we characterized the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical outcomes of patients with unresectable locally advanced non-small cell lung cancer treated on a phase 2 trial of short-course consolidation immunotherapy after CRT, with the goal of testing whether ctDNA may be able to identify patients who do not require a full year of treatment.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Analyzing pts w/unresectable locally advanced #NSCLC on a phase 2 trial of short course consolidation immunotherapy after CRT, the authors found that ctDNA MRD is highly prognostic & might enable personalizing the duration of treatment. https://t.co/KaFvs9VsEI #LCSM @max_diehn https://t.co/V4nhQtbH9Y
-
-
Mashup Score: 2Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400) - 27 day(s) ago
Squamous cell cancer (SqCC) is a lung cancer subtype with few targeted therapy options. Molecular characterization, that is, by next-generation sequencing (NGS), is needed to identify potential targets. Lung Cancer Master Protocol Southwest Oncology Group S1400 enrolled patients with previously treated stage IV or recurrent SqCC to assess NGS biomarkers for therapeutic sub-studies.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
As the largest dataset to date of SqCC profiled on a clinical trial, the Lung-MAP SWOG S1400 NGS dataset establishes a rich resource for biomarker discovery. They enrolled pts w previously treated stage IV or recurrent SqCC for assessment. https://t.co/83VFNVMz41 #LCSM https://t.co/01Oiarvquo
-
-
Mashup Score: 4Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study - 28 day(s) ago
EGFR-mutated NSCLC is minimally responsive to programmed cell death protein 1 or programmed death-ligand 1 blockade. We evaluated the safety, tolerability, and immunomodulatory effects of the EGFR tyrosine kinase inhibitor (TKI) afatinib in combination with the programmed cell death protein 1 antibody pembrolizumab in patients with EGFR-mutant NSCLC.
Source: www.jtocrr.orgCategories: General Medicine News, Oncologists1Tweet-
Afatinib and pembrolizumab were found to have modest activity associated with irAEs after PD on previous EGFR TKI in this Phase IB study. Read more about it here: https://t.co/MnhSHKmEWp #LCSM https://t.co/tnKQBkrPhK
-
-
Mashup Score: 4
Definitive radiation therapy is considered standard therapy for medically inoperable early-stage NSCLC. Nevertheless, for patients with tumors located near structures such as the proximal tracheobronchial tree, esophagus, heart, spinal cord, and brachial plexus, the optimal management regimen is controversial. The objective was to develop expert multidisciplinary consensus guidelines on managing medically inoperable NSCLC located in a central or ultracentral location relative to critical organs at risk.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
The ARS Thoracic AUC panel has developed expert multidisciplinary consensus guidelines on managing medically inoperable #NSCLC located in a central or ultracentral location relative to critical organs at risk. https://t.co/j2VtU86jwI #LCSM @HenryParkMD @YaleRadOnc https://t.co/CMoEGGeK2O
-
-
Mashup Score: 13Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC - 1 month(s) ago
The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of consolidation CPI remains unknown. Here, we characterized the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical outcomes of patients with unresectable locally advanced non-small cell lung cancer treated on a phase 2 trial of short-course consolidation immunotherapy after CRT, with the goal of testing whether ctDNA may be able to identify patients who do not require a full year of treatment.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Analyzing pts w/unresectable locally advanced #NSCLC on a phase 2 trial of short course consolidation immunotherapy after CRT, the authors found that ctDNA MRD is highly prognostic & might enable personalizing the duration of treatment. https://t.co/KaFvs9VsEI #LCSM @max_diehn https://t.co/V4nhQtbH9Y
-
-
Mashup Score: 0
The International Association for the Study of Lung Cancer developed an international database to inform potential revisions in the ninth edition of the TNM classification of diffuse pleural mesothelioma (PM). This study analyzed the clinical and pathologic N categories to determine whether revisions were indicated relative to the eighth edition staging system.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Pleural Mesothelioma Staging Project, 9th Edition: This study analyzed the clinical and pathologic N categories to determine whether revisions were indicated relative to the eighth edition staging system. https://t.co/R3Or2qIzjk #LCSM https://t.co/6m7Ay6BPzt
-
This study aimed to evaluate the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in a large cohort of patients with resected #NSCLC. Read more about the findings here: https://t.co/o4NdaSKtHy #LCSM https://t.co/jfhRsuerCv